Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.59 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | CASR known ✓ | P41180 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.50 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2469805 | 1.00 | SIGMAR1 (0.59) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL607712 | 1.00 | SIGMAR1 (0.59) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| SCHEMBL8437895 | 0.97 | SIGMAR1 (0.61) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| SCHEMBL30763462 | 0.97 | SIGMAR1 (0.61) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| SCHEMBL3749295 | 0.97 | SIGMAR1 (0.61) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| SCHEMBL283979 | 0.97 | SIGMAR1 (0.61) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| SCHEMBL1200137 | 0.97 | SIGMAR1 (0.61) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| SCHEMBL26130571 | 0.97 | SIGMAR1 (0.61) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| SCHEMBL28062957 | 0.90 | SIGMAR1 (0.55) | SIGMAR1ACP3MEN1KMT2ACYP3A4 | |
| SCHEMBL8433113 | 0.86 | SIGMAR1 (0.57) | SIGMAR1ACP3MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | claimed |
| WO-2021210920-A1 | METHOD FOR PRODUCING RAMELTEON, AND INTERMEDIATE COMPOUND USED FOR SAME | 제이투에이치바이오텍 주식회사 | 2021-10-21 | — | — | WO | claimed |
| EP-4727909-A1 | METHODS AND INTERMEDIATES FOR PREPARING COMPOUNDS | VIIV Healthcare UK (No.5) Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20250135005-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | TAMBO INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-12194100-B2 | Processes for preparing functionalized cyclooctenes | TAMBO, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024257009-A1 | METHODS AND INTERMEDIATES FOR PREPARING COMPOUNDS | VIIV Healthcare UK (No.5) Limited (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-11760750-B1 | Process for preparing levoketoconazole | NURAY CHEMICALS PRIVATE LIMITED (IN) | 2023-09-19 | — | — | US | disclosed |
| US-20210346502-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | TAMBO INC (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2021210920-A1 | METHOD FOR PRODUCING RAMELTEON, AND INTERMEDIATE COMPOUND USED FOR SAME | 제이투에이치바이오텍 주식회사 | 2021-10-21 | — | — | WO | disclosed |
| CN-113473975-A | Process for preparing functionalized cyclooctenes | 坦博公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7396953-B2 | Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-07-08 | — | — | US | disclosed |
| US-7345202-B2 | Use of sulfamic acids as resolving agent | AVANTIUM INTERNATIONAL B.V. (NL) | 2008-03-18 | — | — | US | disclosed |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-07-19 | — | — | US | disclosed |
| EP-1392620-B1 | NOVEL USE OF SULFAMIC ACIDS AS RESOLVING AGENT. | AVANTIUM INT BV (NL) | 2007-05-23 | — | — | EP | disclosed |
| US-20040186298-A1 | Novel use of sulfamic acids as resolving agent | AVANTIUM INTERNATIONAL B.V. (NL) | 2004-09-23 | — | — | US | disclosed |
| EP-1392620-A2 | NOVEL USE OF SULFAMIC ACIDS AS RESOLVING AGENT. | Avantium International B.V. (NL) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100804-A2 | NOVEL USE OF SULFAMIC ACIDS AS RESOLVING AGENT. | AVANTIUM INTERNATIONAL, B.V. (NL) | 2002-12-19 | — | — | WO | disclosed |
| EP-1264814-A1 | Resolving agents based on amines | Avantium International B.V. (NL) | 2002-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | ADRB1, ADRB2, ADRA1A | SIGMAR1 257/4885CHRM2 29/4885HTR1A 59/4885 |
| US-12194100-B2 | Processes for preparing functionalized cyclooctenes | PPOX, SCO2, CYCS | SIGMAR1 1093/4885CHRM2 1050/4885HTR1A 3336/4885 |
| US-20070167519-A1 | Novel Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof | FLT1, VEGFA, FGF1 | SIGMAR1 4869/4885CHRM2 4841/4885HTR1A 2058/4885 |
| US-20210346502-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | PPOX, SCO2, CYCS | SIGMAR1 1093/4885CHRM2 1050/4885HTR1A 3336/4885 |
| US-20250135005-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | PPOX, SCO2, CYCS | SIGMAR1 1093/4885CHRM2 1050/4885HTR1A 3336/4885 |
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | ADRB1, ADRA2C, ADRB2 | SIGMAR1 21/4885CHRM2 15/4885HTR1A 31/4885 |
| US-11760750-B1 | Process for preparing levoketoconazole | KHK, KYAT3, PLK3 | SIGMAR1 4149/4885CHRM2 4321/4885HTR1A 3943/4885 |
| US-20040186298-A1 | Novel use of sulfamic acids as resolving agent | HAO1, FPR1, DAO | SIGMAR1 999/4885CHRM2 3238/4885HTR1A 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.